Table 2 Clinicopathological characteristics and adjuvant treatment of EECs with MELF pattern
Total (N = 84) | Surveillance (n = 15) | RT (n = 19) | CT ± RT (n = 50) | p-value | |
|---|---|---|---|---|---|
Age (years) | 59.8 ± 8.27 | 61.3 ± 12.6 | 60.2 ± 8.7 | 59.3 ± 6.4 | 0.31 |
BMI (kg/m2) | 25.9(24.1–28.4) | 25.5(22.7–29.7) | 25.5(24.6–26.9) | 26.4(24.0-28.6) | 0.57 |
TS (cm) | 3.5 (2.5–4.8) | 2.7 (1.5–3.5) | 3.0 (2.5–4.5) | 3.2(2.5-5.0) | 0.71 |
Follow-up time | 26 (12–41) | 24 (6–43) | 21(10–29) | 29(14–45) | 0.79 |
Molecular subtype | 0.071 | ||||
POLEmut | 1 | 1(100%) | 0 | 0 | |
dMMR | 19 | 3(16%) | 7(37%) | 9(47%) | |
NSMP | 53 | 10(19%) | 12(23%) | 31(58%) | |
p53-abn | 11 | 1(9%) | 0 | 10(91%) | |
Stage | 0.411 | ||||
IA | 35 | 9(26%) | 10(28%) | 16(46%) | |
IB | 29 | 5(17%) | 4(14%) | 20(69%) | |
II | 7 | 1(14%) | 2(29%) | 4(57%) | |
III | 11 | 0 | 3(27%) | 8(73%) | |
IV | 2 | 0 | 0 | 2(100%) | |
Risk level | 0.003 | ||||
Low risk | 18 | 8(45%) | 6(33%) | 4(22%) | |
Intermediate risk | 11 | 3(27%) | 2(18%) | 6(55%) | |
High-intermediate risk | 32 | 3(9%) | 8(25%) | 21(66%) | |
High risk | 23 | 1(4%) | 3(13%) | 19(83%) | |
FIGO grade | 0.383 | ||||
G1 | 24 | 6(25%) | 6(25%) | 12(50%) | |
G2 | 47 | 9(19%) | 10(21%) | 28(60%) | |
G3 | 13 | 0 | 3(23%) | 10(77%) | |
MI | 0.144 | ||||
≥ 1/2 | 43 | 9(22%) | 12(29%) | 20(49%) | |
<1/2 | 41 | 6(14%) | 7(16%) | 30(70%) | |
CSI | 0.717 | ||||
Present | 10 | 14(19%) | 16(22%) | 44(59%) | |
Absent | 74 | 1(10%) | 3(30%) | 6(60%) | |
LVSI | 0.100 | ||||
Present | 42 | 11(26%) | 10(24%) | 21(50%) | |
Absent | 42 | 4(10%) | 9(21%) | 29(69%) | |
LN | 0.376 | ||||
Metastasis | 8 | 15(20%) | 17(22%) | 44(58%) | |
Normal | 76 | 0 | 2(25%) | 6(75%) |